HopeStage
Back to all studies
CompletedNCT05454410

Single MIJ821 injection added to treatment-resistant depression care

About this titleRead the official source — NCT05454410
Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Birmingham and 15 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 13, 2023
Recruitment status
Completed
Enrollment listed in the registry
60
Sponsor
Novartis Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Japan, Poland, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT05454410
Official title
Show the full official title

A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Subcutaneous MIJ821 Injection in Addition to Standard of Care in Participants With Treatment-resistant Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham, United States · Oakland Park, United States · Tampa, United States

11 more locations
  • Yokohama, Japan
  • Kodaira, Japan
  • Mitaka, Japan
  • Bialystok, Poland
  • Gdansk, Poland
  • Swiecie North West, Poland
  • Seville, Spain
  • Sabadell, Spain
  • Sant Boi de Llobregat, Spain
  • Barcelona, Spain
  • Pamplona, Spain

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Novartis Pharmaceuticals.

Did this study involve medication?

Yes. The study involved medication, including MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg and Placebo Subcutaneous Injection.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies